Replies to post #164605 on Biotech Values

[genisi]

Teva’s thrice-weekly Copaxone

The UBS analyst (Marc Goodman) also noted as we did (#msg-80403825) that if Copaxone generics enter the market in May 2014, Teva will not have time to switch patients to the thrice-weekly version.